Daré Bioscience, Inc. (DARE), Monday announced that it has received a $4 million non-dilutive funding installment under its multi-year grant agreement to advance DARE-LARC1, a long-acting reversible contraceptive developed using its intelligent drug delivery system, DARE-IDDS platform.
Out of the $49 million allocated for nonclinical development and IND-enabling studies prior to an FDA submission, this brings the total amount of funding received to $41.8 million.
DARE-LARC1 delivers levonorgestrel over long periods of time without daily user intervention using an implantable, programmable device.
Originally created at MIT, the DARE-IDDS platform allows for accurate, wireless, long-term dosing and may find use in treating chronic diseases like diabetes and obesity.
DARE is currently trading at $2.17, down $0.01 or 0.45 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.